Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | OGG1 | O15527 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27710532 | 0.85 | PPARA (0.41) | CYP3A4TSHRPPARAMCL1L3MBTL1 | |
| SCHEMBL9720573 | 0.82 | PPARA (0.46) | CYP3A4TSHRPPARAHPGDL3MBTL1 | |
| SCHEMBL28277550 | 0.80 | PPARA (0.47) | CYP3A4TSHRPPARAHPGDL3MBTL1 | |
| SCHEMBL6812056 | 0.80 | KMT2A (0.51) | CYP3A4PPARAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL17826360 | 0.78 | PPARA (0.44) | CYP3A4TSHRMAOAPPARAL3MBTL1 | |
| SCHEMBL27986848 | 0.78 | PPARA (0.44) | CYP3A4PPARAL3MBTL1MAPTSMN1; SMN2 | |
| SCHEMBL11382828 | 0.78 | MAPT (0.50) | CYP3A4TSHRPPARAHPGDL3MBTL1 | |
| SCHEMBL2278168 | 0.78 | CYP3A4 (0.52) | CYP3A4TSHRMAOAPPARAHPGD | |
| SCHEMBL633305 | 0.77 | TPMT (0.52) | CYP3A4TSHRPPARAL3MBTL1MAPT | |
| SCHEMBL9720564 | 0.76 | ALDH1A1 (0.50) | PPARAHPGDL3MBTL1PPARGMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105906617-A | Modulators of HEC1 activity and methods thereof | 泰纬生命科技股份有限公司 | 2016-08-31 | — | — | CN | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| CN-103038231-A | Modulators of HEC1 activity and methods thereof | TAIVEX THERAPEUTICS INC | 2013-04-10 | — | — | CN | disclosed |
| WO-2011095452-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20100168079-A1 | Biaryl Benzylamine Derivatives | ANGST DANIELA | 2010-07-01 | — | — | US | disclosed |
| US-20100168079-A1 | Biaryl Benzylamine Derivatives | ANGST DANIELA | 2010-07-01 | — | — | US | disclosed |
| US-20100168079-A1 | Biaryl Benzylamine Derivatives | ANGST DANIELA | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | UGT2B7, NAT1, CYP2B6 | CYP3A4 12/4885TSHR 1964/4885CHRM1 1170/4885 |
| US-20100168079-A1 | Biaryl Benzylamine Derivatives | BRD3, BRD2, BBOX1 | CYP3A4 13/4885TSHR 2165/4885CHRM1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.